Ann: Imugene and NeoImmuneTech to Improve Cancer Treatments, page-15

Lol

One of the things I really like about LC and the IMU team - they are always willing to take on something new if it makes strategic sense - either by complementing existing products or by potentially improving them.

It would be far easier to just "keep doing what you are doing," but they do grab new opportunities, and that's why the former one trick pony is now a herd of racehorses I find trouble keeping track of.

I'm sure the increasing complexity of their IP does turn off some investors. People tend to like a simple story. However, every time they do something like this it increases their chances of eventual clinical and commercial success. They are always thinking ahead.

So - we have possibly the world's best allogeneic CAR-T and a good shot at being first in the world to get one to market? Well let's see if we can make it even better....

That's a great attitude to have.

Cheers

Dave